FDA approves first treatment for advanced form of the second most common skin cancer - FDA Press Releases

FDA approves Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.

from Food and Drug Administration--Press Releases https://ift.tt/2DBBan2
via IFTTT